Overcoming Formulation Vulnerability: Chemical Stabilization of Pitavastatin with Alkaline Surface Chemistry

Formulating highly potent HMG-CoA reductase inhibitors (statins) presents significant challenges to pharmaceutical scientists. Among these, Pitavastatin – commercialized globally as Livalo® by the innovator Kowa Pharmaceuticals presents extreme sensitivity to environmental conditions. It requires precise, specialized stabilization strategies to maintain therapeutic efficacy and meet stringent regulatory shelf-life standards.

In this technical newsletter, we examine the stabilization mechanisms detailed in patent US 9,399,064 B2. We explore how modifying microenvironmental pH using Magnesium Aluminometasilicate (Neusilin® S2) protects Pitavastatin from degradation into its less efficacious lactone form.

THE FORMULATION CHALLENGE: PITAVASTATIN DEGRADATION DYNAMICS

The stabilization of Pitavastatin involves addressing two main vulnerabilities:

pH-Dependent Cyclization: Pitavastatin undergoes rapid degradation at a pH < 8 and > 10. In acidic environments, the open-chain hydroxy acid structure undergoes an intramolecular esterification (cyclization) to form a less efficacious lactone impurity. Conversely, highly alkaline environments can lead to discoloration or distinct degradation pathways.
Moisture Sensitivity: Environmental moisture acts as a catalyst, accelerating the rate of hydrolysis and subsequent lactonization.

To prevent this degradation, innovators must control three essential factors during oral solid dosage manufacturing:

Alkaline pH microenvironment (Target range: 8-10) to suppress lactone formation without causing alkaline-induced discoloration.
Advanced Packaging to minimize moisture exposure.
Optimized Compressibility, utilizing low compression forces during tableting to prevent heat build-up, which can thermally accelerate degradation.

CHEMICAL STRUCTURE AND THE CORE FORMULA

The molecular framework of Pitavastatin relies on balancing the drug substance against its primary degrade. Pitavastatin is typically supplied as a hemi-calcium salt. Its chemical nomenclature is Monocalcium bis{(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate}.

The Balance of Interconversion

The chemical equation representing the transition between the active therapeutic form and the degradation product within oral solid dosages can be structurally represented as follows:

By introducing a basic additive that stabilizes the local surface chemistry, the equilibrium is shifted toward the left, ensuring the therapeutic integrity of the molecule.

THE INNOVATOR’S CHOICE: NEUSILIN® S2

To address these challenges, the innovator product Livalo® (Kowa Pharmaceuticals) incorporates Magnesium Aluminometasilicate (Neusilin® S2) into its product. Neusilin® S2 is a synthetic, amorphous form of Magnesium Aluminometasilicate featuring high performance properties. Fuji Chemical Industries proposes Neusilin® S2 as a multifunctional excipient to protect unstable statins through several key mechanisms:

Three Key Benefits for Optimal Product Stability

Neusilin® S2 maintains optimal pH, provides superior protection, and controls moisture ensuring maximum stability, potency, and quality of pitavastatin.

Continue reading and see the full Pharmaceutical Technical Newsletter on Overcoming Formulation Vulnerability: Chemical Stabilization of Pitavastatin with Alkaline Surface Chemistry here:

(click the picture to download the technical newsletter)

Do you need more information or a sample of Fuji Chemical Industries excipients?

Name *

First

Last

Email *

Company *

Address

Address Line 1

Address Line 2

City

State / Province / Region

Postal Code

Country

Comment or Message *

I agree with the privacy policy as per https://www.pharmaexcipients.com/privacy/ . The contact details will be shared with the supplier who holds the request above. The supplier can contact you directly.